[Combined radio-chemotherapy in solid tumour treatment of advanced bladder cancer (preliminary report)].
Radiotherapy combined with platinum compounds in widely used despite unclear biological basis and mechanism of their potentiation. We started a prospective nonrandom study on January 1, 1991 with the aim to ameliorate local tumour control and possibility of curative treatment, and treatment of toxicyty.


METHODS
82 patients with locally advanced bladder cancer (stage T3 and localizet T4) were treated with radiochemotherapy. Median age was 62 years, and male female radio was 3.5:1. The whole group had transitpy cell carcinoma, grade III, with primary tumour in 56 patients and solitary tumour in 51 patients.


METHODS
External beam radiotherapy was performed on linear accelerator with locoregional technique, conventional fractionating and tumour dose of 65 Gy. On the lifth day of radiotherapy a 20 mg i.v. bolus Cisplatin 1 hour prior radiotherapy was administered to 49 patients. Total dose of Cisplatin was 120 mg per course. Carboplatin was given (75 mg i.v.) to 12 patients in the same way like Cisplatin, with total dose od 450 mg. In 21 patients Carboplatin was administered in a dose of 150 mg (fifth day) during radiotherapy, and total dose was 900 mg.
The toxicity was mild in both groups of patients: 2/49 patients in Cisplatin group experienced nausea and 2/49 experienced haematological toxicity grade II as wel as 5/33 patients from Carboplatin group.


RESULTS
Tumours complete regression was observed in 69.4% of patients in Cisplatin group and in 84.6% in Carboplatin group. Mean follow-up was 14 months in Cisplatin group and overall survival was 77% at a 2-year interval, these results are not-suphicicent for the binal conclusion conserning the late complications and the clinical benefit, but the treatment was well tolerated. We intend to increase Carboplatin dose in our fur ther study.
Radosević-Jelić
Lj
Lj
Pekmezović
T
T
Borkovacki
R
R
Sobić
V
V
Petronić
V
V
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016190:Carboplatin / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000532:radiotherapy; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*
D000970:Antineoplastic Agents; D016190:Carboplatin; D002945:Cisplatin